• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs

tetano

Editor, Senior Moderator
Langzhou Song1*, Valerian Nakaar2, Uma Kavita1, Albert Price2, Jim Huleatt2?, Jie Tang2, Andrea Jacobs2, Ge Liu1, Yan Huang2, Priyanka Desai2, Gail Maksymiuk2, Virginia Takahashi2, Scott Umlauf1, Lucia Reiserova1, Rodney Bell1, Hong Li1, Yi Zhang1, William F. McDonald2, T. J. Powell2, Lynda Tussey1

1 VaxInnate Corporation, Cranbury, New Jersey, United States of America, 2 VaxInnate Corporation, New Haven, Connecticut, United States of America
Abstract Top

It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.

Citation: Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs. PLoS ONE 3(5): e2257. doi:10.1371/journal.pone.0002257

http://www.plosone.org/article/info...7;jsessionid=66F380CC028AA330385C54C3B25AE539
 
Back
Top Bottom